NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocular Therapeutix, Inc. (NASDAQ: OCUL) resulting from allegations that Ocular Therapeutix may have issued materially misleading business information to the investing public.
On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant, but downplayed any concerns. On July 6, 2017, Seeking Alpha published an article asserting that Ocular Therapeutix’s management has been misleading investors about manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product. On this news, shares of Ocular Therapeutix fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Ocular Therapeutix investors. If you purchased shares of Ocular Therapeutix on or before July 6, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1158.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.